MedTrace Logo

A Study of Single and Multiple Ascending Doses of KBL697 in Healthy Subjects

NCT04056130 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2021-09-08

No results posted yet for this study

Summary

The study is designed to investigate the safety and tolerability of KBL697 in healthy volunteers. KBL697 has been developed as a potential new treatment for atopic dermatitis (AD).

Conditions

  • Atopic Dermatitis (AD)

Interventions

DRUG

KBL697

Part A: 1 day 460mg/day of KBL697 or placebo Route of Administration: Oral

DRUG

KBL697

Part A: 1 day 4,600mg/day of KBL697 Route of Administration: Oral

DRUG

KBL697

Part B: 14 days Cohort MAD1: 460mg/day of KBL697 Route of Administration: Oral

DRUG

KBL697

Part B: 14 days Cohort MAD2: 4,600mg/day of KBL697 Route of Administration: Oral

Sponsors & Collaborators

  • Novotech (Australia) Pty Limited

    collaborator INDUSTRY

  • KoBioLabs

    lead INDUSTRY

Principal Investigators

  • Ben Snyder, Dr · Nucleus Network

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-10-04
Primary Completion
2019-12-23
Completion
2020-01-07

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04056130 on ClinicalTrials.gov